A Study of Eloralintide (LY3841136) in Healthy Participants

This study is looking for healthy volunteers aged 18 to 65 with a BMI between 20 and 32 to help us understand Eloralintide (LY3841136). We want to learn about its safety, how well your body tolerates it, and how your body processes two different solutions of Eloralintide. The main goals are to measure how much of the drug is in your body over time (Pharmacokinetics or PK) and its highest concentration (Cmax). The study's current status is unclear, but it plans to enroll 58 participants. You cannot join if you have known allergies to Eloralintide or its components, or a significant medical history.

Study design: This is an interventional study planning to enroll 58 healthy participants. The phase of the study is not specified.
What's involved: Participation will last about 13 weeks, including screening, inpatient treatment, and follow-up visits.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoints for measuring Eloralintide levels are from predose on Day 1 through Day 57.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

A Study of Eloralintide (LY3841136) in Healthy Participants

Recruiting

PHASE1Ages 18–65InterventionalBasic science

Eli Lilly and Company

~58 participants

Updated 2026-08-20 on ClinicalTrials.gov

What's tested:Eloralintide

At a glance

Recruiting sites

2 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide

Measured over Predose on Day 1 through Day 57

+1 more outcome measured

Conditions

Healthy Volunteers

NCT07701083

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Fortrea Clinical Research Unit
Daytona Beach, Floridastudy coordinator listed
Recruiting
Fortrea Clinical Research Unit
Dallas, Texasstudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

[email protected]

1-317-615-4559

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Are overtly healthy as determined by medical evaluation

Have a body mass index (BMI) within the range of 20.0 to 32.0 kilogram per square meter (kg/m2), inclusive

Exclusion

Have known allergies to related compounds of eloralintide, or any of the components of the formulations

Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data

Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have glycated hemoglobin greater than or equal to 6.5% or 48 millimole per mole (mmol/mol)

Have a history of any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years

Have a history or presence of a gastrointestinal (GI) disorder or previous surgery that impacts gastric emptying for example, gastric bypass surgery or pyloric stenosis

Have obesity induced by other endocrinologic disorders for example, Cushing syndrome, or diagnosed monogenetic or syndromic forms of obesity for example, Melanocortin 4 Receptor deficiency or Prader Willi syndrome

Have taken approved or investigational medication for weight loss, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), within the previous 3 months of study screening

Intend to use any weight loss medications during study participation

What this trial measures

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of EloralintidePredose on Day 1 through Day 57
PK: Maximum Concentration (Cmax) of EloralintidePredose on Day 1 through Day 57

Trialytics